Literature DB >> 20462603

Pretreatment of vitamin D3 ameliorates lung and muscle injury induced by reperfusion of bilateral femoral vessels in a rat model.

Pin-Keng Shih1, Yi-Ching Chen, Ya-Chun Huang, Yu-Tang Chang, Jian-Xun Chen, Chih-Mei Cheng.   

Abstract

BACKGROUND: Peripheral arterial occlusive disease (PAOD) is a challenge in peripheral vascular disease. Clinical observations show reperfusion of occluded vessels may cause compartment syndrome or remote organ injury. Less well known is the role of vitamin D3 in tissue injury; therefore, we attempted to determine whether vitamin D3 could alleviate local and remote organ injury induced by reperfusion of occluded vessels in animal models.
METHODS: Twenty-four male Sprague-Dawley rats were randomized into four groups: saline + sham, saline + I/R, vitamin D3 + sham, and vitamin D3 + I/R group. After pretreatment for 5 d, the animals designed to I/R injury were subjected to 3 h of ischemia induced by bilateral femoral arteries clamp, followed by reperfusion of the vessels for 3 h on d 6. Left lung and left anterior tibial muscle tissue were harvested for wet/dry weight ratio and histopathologic analysis. Blood was collected for analysis of urea nitrogen (BUN), creatinine (Cr), aspartate aminotransferase (AST), alanine aminotransferase (ALT), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), ionized calcium levels, and heme oxygenase-1 (HO-1).
RESULTS: Compared with the saline + sham group, there was a significant increase in plasma IL-6 level in both saline + I/R and vitamin D3 + I/R groups and muscle, lung wet/dry weight ratio in the saline + I/R group (P < 0.05). Compared with the saline + I/R group, there was a significant decrease in plasma IL-6 level, muscle and lung wet/dry weight ratio in both vitamin D3 + sham and vitamin D3 + I/R groups, and leukocyte HO-1 expression in vitamin D3 + sham group (P < 0.05). Compared with the vitamin D3 + sham group, there was a significant increase in plasma IL-6 levels in the vitamin D3 + I/R group, and leukocyte HO-1 expression in vitamin D3 + sham group (P < 0.05). BUN, Cr, AST, ALT, TNF-α, ionized calcium levels did not differ significantly among the groups.
CONCLUSIONS: Pretreatment of vitamin D3 ameliorates the systemic IL-6 levels, lung and muscle injury induced by ischemia followed by reperfusion of bilateral occluded vessels in a rat model.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20462603     DOI: 10.1016/j.jss.2010.03.008

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  Vitamin D ameliorates hepatic ischemic/reperfusion injury in rats.

Authors:  Ansam Aly Seif; Doaa Mohamed Abdelwahed
Journal:  J Physiol Biochem       Date:  2014-04-22       Impact factor: 4.158

Review 2.  The beneficial role of vitamin D in systemic lupus erythematosus (SLE).

Authors:  Khanh vinh quốc Luong; Lan Thi Hoàng Nguyễn
Journal:  Clin Rheumatol       Date:  2012-07-17       Impact factor: 2.980

3.  The emerging role of vitamin D3 in protecting ischemic tissues.

Authors:  Jeffrey A Poynter
Journal:  J Surg Res       Date:  2010-09-16       Impact factor: 2.192

4.  Lipopolysaccharide-induced lung injury is independent of serum vitamin D concentration.

Authors:  Lindy S Klaff; Sean E Gill; Brent E Wisse; Kristen Mittelsteadt; Gustavo Matute-Bello; Peter Chen; William A Altemeier
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

Review 5.  Roles of vitamin D in amyotrophic lateral sclerosis: possible genetic and cellular signaling mechanisms.

Authors:  Khanh vinh quốc Long; Lan Thi Hoàng Nguyễn
Journal:  Mol Brain       Date:  2013-04-09       Impact factor: 4.041

6.  Vitamin D/VDR signaling attenuates lipopolysaccharide‑induced acute lung injury by maintaining the integrity of the pulmonary epithelial barrier.

Authors:  Yong-Yan Shi; Tian-Jing Liu; Jian-Hua Fu; Wei Xu; Lin-Lin Wu; A-Na Hou; Xin-Dong Xue
Journal:  Mol Med Rep       Date:  2015-12-14       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.